JW SHINYAK (South Korea) Profile

Performance

1414
   

Odds of Distress

Check how we calculate scores
Equity ratings for JW SHINYAK are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting August 21, 2019 and ending today November 19, 2019. Click here to learn more.

JW SHINYAK Profile

JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. It also develops prostate cancer treatment, liver cancer treatment, rheumatoid arthritis treatment, etc. JW SHINYAK is traded on Korean Securities Dealers Automated Quotations in South Korea. more
NameJW SHINYAK
Co-CEO, DirectorGyeong LeeView All
Macroaxis Advice
InstrumentSouth Korea Stock View All
Business Address2477, Nambusunhwan-ro
ExchangeKorean Securities Dealers Automated Quotations
BenchmarkDOW
Websitewww.jw-shinyak.co.kr
Phone82 2 2109 3300
CurrencyKRW - South Korean Won
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
JW SHINYAK (067290) is traded on Korean Securities Dealers Automated Quotations in South Korea and employs 8 people. The company currently falls under 'Mega-Cap' category with current market capitalization of 201.92 B. JW SHINYAK has 41.55 M outstanding shares. CWSY has accumulated about 3.65 B in cash with 4.64 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 87.91.
Check JW SHINYAK Probability Of Bankruptcy

JW SHINYAK Target Price Odds Analysis

Odds Below 4815.0HorizonTargetOdds Above 4815.0
14.96%30 days 4,815 84.99%
Based on normal probability distribution, the odds of JW SHINYAK to move above current price in 30 days from now is about 84.99 (This JW SHINYAK probability density function shows the probability of JW SHINYAK Stock to fall within a particular range of prices over 30 days) .

JW SHINYAK Risk Profiles

JW SHINYAK Key Fundamentals

JW SHINYAK Against Markets

JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. It also develops prostate cancer treatment, liver cancer treatment, rheumatoid arthritis treatment, etc. JW SHINYAK is traded on Korean Securities Dealers Automated Quotations in South Korea. more
NameJW SHINYAK
Co-CEO, DirectorGyeong LeeView All
Macroaxis Advice
InstrumentSouth Korea Stock View All
Business Address2477, Nambusunhwan-ro
ExchangeKorean Securities Dealers Automated Quotations
BenchmarkDOW
Websitewww.jw-shinyak.co.kr
Phone82 2 2109 3300
CurrencyKRW - South Korean Won
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018

JW SHINYAK Corporate Directors

Jong Lee Director
Sang Han Director
Cheol Han Director
Check also Trending Equities. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.
Search macroaxis.com